Jul 10,2019

Nemaura Medical Inc. Submits De Novo 510(k) Application for SugarBEAT® to the U.S. Food and Drug Administration

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it has submitted its De Novo 510(k) medical device application to the U.S. Food & Drug Administration for SugarBEAT® following the successful completion of clinical studies and two summative human factors usability studies for SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 16,2019

AI In Healthcare Use Case #30: Sweetch

In this interview, Dana Chanan, co-founder and CEO of Sweetch, explains how his company is using AI to transform healthcare, and what the future of the industry holds.

View Analyst & Ambassador Comments
Go to original news
Jul 17,2019

ABBOTT REPORTS SECOND-QUARTER 2019 RESULTS

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2019. Company's second-quarter worldwide sales of $8.0 billion increased 2.7 percent on a reported basis and 7.5 percent on an organic basis. In Diabetes Care, sales increased 28.2 percent on a reported basis and 35.3 percent on an organic basis in the second quarter. Sales growth in the quarter was led by FreeStyle Libre, Abbott's revolutionary continuous glucose monitoring system, with worldwide sales of $433 million, an increase of 63.9 percent on a reported basis and 72.9 percent on an organic basis versus the prior year.

View Analyst & Ambassador Comments
Go to original news
Jul 17,2019

Insulet to Debut New Educational Self-Advocacy Tool at 20th Annual Children with Diabetes Friends for Life Conference

Insulet Corporation, the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will launch a new microsite, www.advocacyforaccess.com with a focus on educating, empowering, and mobilizing the diabetes community to drive affordable access to medical devices and medications. The site will be launched in connection with the Company’s participation at the 20th Annual Children with Diabetes Friends for Life conference taking place in Orlando, Florida, July 17-19, 2019.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jul 18,2019

Nemaura Medical Inc. Appoints Chris Avery as Vice President of Global Business Operations to Support Global Commercial Launch of SugarBEAT®

Mr. Avery brings over 30 years of senior experience in the healthcare industry with a focus on launching products, establishing distribution channels, and developing international relationships. Previously, Mr. Avery co-founded DiagnoSys Medical, a UK medical device distribution company. In this role, Mr. Avery recruited, trained, and launched a field-based sales team and was responsible for negotiating the sale of the business to Home Diagnostics.

View Analyst & Ambassador Comments
Go to original news
Jul 19,2019

Tandem Diabetes Care to Announce Second Quarter 2019 Financial Results on August 1, 2019

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its second quarter 2019 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Jul 22,2019

BD Board Declares Dividends

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on September 9, 2019. The indicated annual dividend rate is $3.08 per share. In addition, the Board of Directors has declared a quarterly dividend of $15.3125 per share on the 6.125% mandatory convertible preferred stock, Series A, payable on November 1, 2019 to holders of record on October 15, 2019. This represents $0.7656 per depositary share (NYSE: BDXA).

View Analyst & Ambassador Comments
Go to original news
Jul 23,2019

Medtronic Requests Approval of Non-Adjunctive Labeling from FDA

Medtronic plc(opens new window) (NYSE:MDT), the global leader in medical technology, services and solutions, today announced its Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA) requesting approval for non-adjunctive labeling for its Guardian™ Sensor 3, as part of the MiniMed™ 670G system. If the FDA approves a sensor with non-adjunctive labeling, it means that a sensor is accurate enough to be used to calculate an insulin dose for meals and to correct high glucose levels. Since Medicare requires a non-adjunctive label for sensor reimbursement, if approved, this labeling could broaden patient access by allowing for Medicare coverage of the world’s first and still the only commercially available hybrid closed loop system.

PRODUCT

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 24,2019

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming investor conferences: The 39th Annual Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 7, 2019, at 2:30 p.m. (Eastern Time); The Baird 2019 Global Healthcare Conference in New York City, NY on Thursday, September 5, 2019, at 8:30 a.m. (Eastern Time); The 17th Annual Morgan Stanley Global Healthcare Conference in New York City, NY on Tuesday, September 10, 2019, at 11:45 a.m. (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 25,2019

DarioHealth USB Type C Connector for the European Android Market Is CE Marked

Global digital therapeutics innovator DarioHealth Corp. (Nasdaq: DRIO), today announced that its CE certificate covers a USB-C connector enabled version of the acclaimed Dario™ Blood Glucose Monitoring System. The USB-C connector is used to transfer power and communication signals between Android smart mobile devices and the Dario meter, and ensures that consumers, beginning with the Europe market region, will receive the same quality user experience with DarioHealth on the latest Android smart phone devices.

REGULATORY CE MARK

#bgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES